Reports
Sale
North America Epilepsy Drugs Market Size, Share, Forecast: By Seizure Type: Focal Seizures, Generalized Seizures, Non-epileptic Seizures, Others; By Drug Generation: First Generation Drugs, Second Generation Drugs, Others; By Age Group; By Route of Administration; By Distribution Channel; Regional Analysis; Supplier Landscape; 2024-2032
North America Epilepsy Drugs Market Size
The North America epilepsy drugs market is expected to grow at a CAGR of 4.30% during the forecast period of 2024-2032, driven by increased clinical trials and research initiatives to introduce novel anti-epileptic drugs in the region.
North America Epilepsy Drugs Market Outlook
- One of the major market trends is the rising entry of generic equivalents of popular epilepsy medications.
- The surge in clinical trials to introduce novel epilepsy drugs with better efficacy and minimal side effects is poised to fuel the North America epilepsy drugs market demand.
- In the United States, around 3 million people are reported to suffer from epilepsy. The growing number of epilepsy cases coupled with heightened patient awareness is driving the market growth.
North America Epilepsy Drugs Market Analysis
Epilepsy is a common neurological condition characterized by recurrent seizures. This chronic noncommunicable disease can occur in people of all ages and is known to affect 50 million individuals worldwide. In the United States, around 3 million people are reported to suffer from epilepsy. The growing number of epilepsy cases coupled with the heightened patient awareness is contributing to the global epilepsy drugs market. Further, it is estimated that 70% of epilepsy patients could live seizure-free following appropriate diagnosis and treatment, indicating the need for effective epilepsy drugs. The rising advancements in drug development supported by the increased research funding and robust government initiatives are expected to drive the North America epilepsy drugs market growth.
Growth in clinical trials to introduce novel epilepsy drugs with better efficacy and minimal side effects is poised to shape the market landscape in coming years. In October 2023, the results of a phase 2b clinical trial of Xenon Pharmaceutical’s (a Canadian neuroscience-focused biopharmaceutical company) investigational drug XEN1101 demonstrated a reduction in seizure frequency by more than 50% in certain epilepsy patients and sometimes even eliminated them altogether. The study, conducted by the researchers at NYU Grossman School of Medicine (a medical school of New York University), also showed that the new oral drug can be started at its most effective dose, unlike other epilepsy treatments that have to be gradually ramped up. Increased clinical trial activities focused on evaluating the clinical outcomes of innovative epilepsy therapeutics is projected to boost the market value in the forecast period.
One of the major North America epilepsy drugs market trends is the rising entry of generic equivalents of popular epilepsy medications. For example, in December 2023, an Indian multinational pharmaceutical company Zydus Lifesciences Limited received US Food and Drug Administration (FDA) approval to manufacture and market a generic version of anti-epileptic medication, Lacosamide Tablets, in multiple strengths. The drug is indicated for the treatment of partial-onset seizures and is also used in combination with other medicines to treat primary generalized tonic-clonic seizures. Since generic medications are generally sold at lower prices than brand-name drugs, this market trend is anticipated to increase the accessibility of essential epilepsy treatment options and thereby augment the market demand.
North America Epilepsy Drugs Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
| Market Breakup | Categories |
| Seizure Type | Focal Seizures, Generalized Seizures, Non-Epileptic Seizures, Others |
| Drug Generation | First Generation Drugs, Second Generation Drugs, Third Generation Drugs |
| Age Group | Pediatric, Adult |
| Route of Administration | Oral, Nasal, Injectable, Rectal, Others |
| Distribution Channel | Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers |
| Countries | United States of America, Canada |
Leading Players in the North America Epilepsy Drugs Market
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
UCB SA
UCB (Union Chimique Belge) is a multinational biopharmaceutical company that specializes in the research and development of epilepsy treatments. In March 2022, the U.S. Food and Drug Administration (FDA) approved its drug (branded as Fintepla) to treat seizures associated with a rare form of childhood epilepsy, Lennox-Gastaut Syndrome (LGS).
Novartis AG
This Swiss multinational pharmaceutical corporation's drug asset TRILEPTAL is indicated for monotherapy or adjunctive therapy in adults to treat partial-onset seizures.
Pfizer Inc.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered in New York City and is actively involved in the development of epilepsy drugs. Its anti-epileptic medication Zarontin (ethosuximide) is used alone or in combination with other medicines to treat absence seizures in adults and children.
GSK Plc
The British multinational pharmaceutical and biotechnology company is known for its oral solution Keppra, indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization. It can be taken by adults and adolescents 16 years or above with newly diagnosed epilepsy.
Other players in the market include Abbott Laboratories, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd., Catalyst Pharmaceuticals Inc., and Alkem Laboratories Ltd.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Seizure Type |
|
| Breakup by Drug Generation |
|
| Breakup by Age Group |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
North America Epilepsy Drugs Market Report Snapshots
North America Epilepsy Drugs Market Size
North America Epilepsy Drugs Market Analysis
North America Epilepsy Drugs Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 North America Epilepsy Drugs Market Overview
3.1 North America Epilepsy Drugs Market Historical Value (2017-2023)
3.2 North America Epilepsy Drugs Market Forecast Value (2024-2032)
4 North America Epilepsy Drugs Market Landscape*
4.1 North America Epilepsy Drugs Market: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 North America Epilepsy Drugs Market: Product Landscape
4.2.1 Analysis by Seizure Type
4.2.2 Analysis by Drug Generation
5 North America Epilepsy Drugs Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Analysis
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 North America Epilepsy Drugs Market Segmentation (2017-2032)
6.1 North America Epilepsy Drugs Market (2017-2032) by Seizure Type
6.1.1 Market Overview
6.1.2 Focal Seizures
6.1.3 Generalized Seizures
6.1.4 Non-epileptic Seizures
6.1.5 Others
6.2 North America Epilepsy Drugs Market (2017-2032) by Drug Generation
6.2.1 Market Overview
6.2.2 First Generation Drugs
6.2.3 Second Generation Drugs
6.2.4 Third Generation Drugs
6.3 North America Epilepsy Drugs Market (2017-2032) by Age Group
6.3.1 Market Overview
6.3.2 Pediatric
6.3.3 Adult
6.4 North America Epilepsy Drugs Market (2017-2032) by Route of Administration
6.4.1 Market Overview
6.4.2 Oral
6.4.3 Nasal
6.4.4 Injectable
6.4.5 Rectal
6.4.6 Others
6.5 North America Epilepsy Drugs Market (2017-2032) by Distribution Channel
6.5.1 Market Overview
6.5.2 Hospital Pharmacies
6.5.3 Drug Stores and Retail Pharmacies
6.5.4 Online Providers
6.6 North America Epilepsy Drugs Market (2017-2032) by Countries
6.6.1 Market Overview
6.6.2 United States of America
6.6.3 Canada
7 United States of America Epilepsy Drugs Market (2017-2032)
7.1 United States of America Epilepsy Drugs Market (2017-2032) by Seizure Type
7.1.1 Market Overview
7.1.2 Focal Seizures
7.1.3 Generalized Seizures
7.1.4 Non-epileptic Seizures
7.1.5 Others
7.2 United State of America Epilepsy Drugs Market (2017-2032) by Drug Generation
7.2.1 Market Overview
7.2.2 First Generation Drugs
7.2.3 Second Generation Drugs
7.2.4 Third Generation Drugs
7.3 United State of America Epilepsy Drugs Market (2017-2032) by Age Group
7.3.1 Market Overview
7.3.2 Pediatric
7.3.3 Adult
7.4 United States of America Epilepsy Drugs Market (2017-2032) by Route of Administration
7.4.1 Market Overview
7.4.2 Oral
7.4.3 Nasal
7.4.4 Injectable
7.4.5 Rectal
7.4.6 Others
7.5 United States of America Epilepsy Drugs Market (2017-2032) by Distribution Channel
7.5.1 Market Overview
7.5.2 Hospital Pharmacies
7.5.3 Drug Stores and Retail Pharmacies
7.5.4 Online Providers
8 Canada Epilepsy Drugs Market (2017-2032)
8.1 Canada Epilepsy Drugs Market (2017-2032) by Seizure Type
8.1.1 Market Overview
8.1.2 Focal Seizures
8.1.3 Generalized Seizures
8.1.4 Non-epileptic Seizures
8.1.5 Others
8.2 Canada Epilepsy Drugs Market (2017-2032) by Drug Generation
8.2.1 Market Overview
8.2.2 First Generation Drugs
8.2.3 Second Generation Drugs
8.2.4 Third Generation Drugs
8.3 Canada Epilepsy Drugs Market (2017-2032) by Age Group
8.3.1 Market Overview
8.3.2 Pediatric
8.3.3 Adult
8.4 Canada Epilepsy Drugs Market (2017-2032) by Route of Administration
8.4.1 Market Overview
8.4.2 Oral
8.4.3 Nasal
8.4.4 Injectable
8.4.5 Rectal
8.4.6 Others
8.5 Canada Epilepsy Drugs Market (2017-2032) by Distribution Channel
8.5.1 Market Overview
8.5.2 Hospital Pharmacies
8.5.3 Drug Stores and Retail Pharmacies
8.5.4 Online Providers
9 Regulatory Framework
10 Patent Analysis
10.1 Analysis by Type of Patent
10.2 Analysis by Publication year
10.3 Analysis by Issuing Authority
10.4 Analysis by Patent Age
10.5 Analysis by CPC Analysis
10.6 Analysis by Patent Valuation
10.7 Analysis by Key Players
11 Funding and Investment Analysis
11.1 Analysis by Funding Instances
11.2 Analysis by Type of Funding
11.3 Analysis by Funding Amount
11.4 Analysis by Leading Players
11.5 Analysis by Leading Investors
11.6 Analysis by Geography
12 Partnership and Collaborations Analysis
12.1 Analysis by Partnership Instances
12.2 Analysis by Type of Partnership
12.3 Analysis by Leading Players
12.4 Analysis by Geography
13 Supplier Landscape
13.1 Market Share by Top 5 Companies
13.2 UCB SA
13.2.1 Financial Analysis
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 Novartis AG
13.3.1 Financial Analysis
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Pfizer Inc.
13.4.1 Financial Analysis
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 GSK Plc
13.5.1 Financial Analysis
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Abbott Laboratories
13.6.1 Financial Analysis
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Sanofi SA
13.7.1 Financial Analysis
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Sumitomo Pharma America Inc.
13.8.1 Financial Analysis
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Teva Pharmaceutical Industries Ltd
13.9.1 Financial Analysis
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Catalyst Pharmaceuticals Inc
13.10.1 Financial Analysis
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Alkem Laboratories Ltd
13.11.1 Financial Analysis
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
14 North America Epilepsy Drugs Market – Distribution Model (Additional Insight)
14.1 Overview
14.2 Potential Distributors
14.3 Key Parameters for Distribution Partner Assessment
15 Key Opinion Leaders (KOL) Insights (Additional Insight)
16 Company Competitiveness Analysis (Additional Insight)
16.1 Very Small Companies
16.2 Small Companies
16.3 Mid-Sized Companies
16.4 Large Companies
16.5 Very Large Companies
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4.30% during the forecast period of 2024-2032, driven by increased clinical trials and research initiatives to introduce novel anti-epileptic drugs in the region.
Rising healthcare expenditure and heightened patient awareness are fuelling the demand for the market.
One of the market significant trends is the rising entry of generic equivalents of epilepsy medications. For example, in December 2023, United States FDA approved Zydus Lifesciences Limited to manufacture and market a generic version of anti-epileptic medication, Lacosamide Tablets, in multiple strengths.
Based on the seizure type, the market is segmented into focal seizures, generalized seizures, and non-epileptic seizures, among others.
By drug generation, the market is divided into first generation drugs, second generation drugs, and third generation drugs.
By age group, the market is divided into pediatric and adult.
The market breakup by route of administration includes oral, nasal, injectable, and rectal, among others.
Distribution channels of the market are hospital pharmacies, drug stores and retail pharmacies, and online providers.
The market segmentation by countries includes the United States of America and Canada.
The key players in the market are UCB SA, Novartis AG, Pfizer Inc., GSK Plc, Abbott Laboratories, Sanofi SA, Sumitomo Pharma America Inc., Teva Pharmaceutical Industries Ltd., Catalyst Pharmaceuticals Inc., and Alkem Laboratories Ltd.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2639
$2399
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 4399
$3999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 5829
$5299
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 6929
$6299
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER